Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 12, 2005. The report details a specific corporate action regarding the repurchase of the company's own shares, executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 800,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,440.99 pence per share.
- Treasury Shares Held: 135,508,000 shares (post-transaction).
- Shares in Issue: 5,823,910,917 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 800,000 shares on December 12, 2005, and intends to hold them in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 800,000 share repurchase (800,000 shares x 1,440.99 pence).
- Confirm the updated total share capital and Treasury holdings in subsequent filings.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the authorized buyback program.
- Note that this filing does not contain quarterly or annual financial performance data.